Immupharma Share Discussion Threads

[hamhamham1] 22/2/2018 15:51

From that tip the other day...
I want to press home that there is also the potential for a trial failure and although the drug has other potential uses in treating rheumatoid arthritis, Crohn's disease and asthma, for my NAP purposes I need good results to propel the shares this year and so this is really a single shot at the goal.

[hottingup] 22/2/2018 15:45

This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
Tue. 26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

[hottingup] 22/2/2018 15:45

Shares Magazine
Small caps poised for big news in 2018:
We look at 19 stocks primed to deliver major events in their career
21/12/2017



"Drug developer ImmuPharma (IMM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators."

[ny boy] 22/2/2018 15:44

This is amazing news from an actual patient on a previous trial phase.

We are warming up fast, investor evening Monday night, I am sure TPI will want the share price over 144p to avoid potential embarrassment over the placing!

[money maker1] 22/2/2018 15:43

Millions of lupus suffers urgently need IMM's wonder drug Lupuzor.

[money maker1] 22/2/2018 15:32

From somone we know took Lupuzor!!

[money maker1] 22/2/2018 15:32

top tips
22 Feb '18 - 14:58 - 15223 of 15230

Barbie Manchester

Woman, Barbie Manchester from North Carolina, with terminal Lupus took Lupuzor, with the result she didn't know she was ill during that time. Since then she has had other treatments none of which gave the benefits of lupuzor:



The drug administered in her first trial, Lupuzor, worked well. But after three years, the trial ended. “That was very devastating,” she said. “For me personally, that was the best medication. You’d never have known I was sick.”

[ny boy] 22/2/2018 15:31

I think we know there is a high of success for top line results to be announced.

For sure less than a month to go

[55nobby] 22/2/2018 15:24

People seem eager to continue taking Lupuzor. It must be working well.

[waterloo01] 22/2/2018 15:06

No you are right they have also started recruitment into 4 of the centres.

[bermudashorts] 22/2/2018 15:06

Tosh,

re. Your 15219 - agreed

[teddy boy1] 22/2/2018 15:04

Buying seems to have slowed right down Is it that the short is now completed? Seems that way to me!

[bermudashorts] 22/2/2018 15:03

Waterloo - re. your 15216. Think the CT No. was added back on 11th Feb. Usually details of changes aren't added until the next day. You may be right, I'll check again tomorrow.

By the way, interesting link earlier - thanks.

[top tips] 22/2/2018 14:58

Barbie Manchester

Woman, Barbie Manchester from North Carolina, with terminal Lupus took Lupuzor, with the result she didn't know she was ill during that time. Since then she has had other treatments none of which gave the benefits of lupuzor:



The drug administered in her first trial, Lupuzor, worked well. But after three years, the trial ended. “That was very devastating,” she said. “For me personally, that was the best medication. You’d never have known I was sick.”

Melanie Regnaud

Young woman, Melanie Regnaud, a longstanding lupus sufferer took Lupuzor and gets better. Now leading a normal life & has her first ever boyfriend:

May 2017 article -
hxxp://www.objectifsante.mu/article/3295/melanie-regnaud-ceci-est-ma-lutte-contre-le-lupus&prev=search' target='window'>hTTps://translate.google.co.uk/translate?hl=en&sl=fr&u=

[hamhamham1] 22/2/2018 14:57

Tt. Well thats wjat the inital length is. GSK/benlysta are 5 years into their open extension, am sure it started off shorter time?

[top tips] 22/2/2018 14:55

The extension study is only for 6 months per patient.

[hamhamham1] 22/2/2018 14:54

Hopefully one of the questions you guys/girls are going to ask at the meeting regarding the £10m placement is what is it going to be spent on and what is the costs of the open extension for 6 months, 12 months, etc?

[tosh 123] 22/2/2018 14:52

Bermuda
great find. This bit of information, if nothing else, somewhat confirms " no side effects ".
Much as I would love to say that Prof Bang Bang is right, and that this also confirms that Lupizor is working, unfortunately, we cant draw that conclusion from this new development... at the moment ... however, it would appear somewhat misguided to enroll another 100 patients onto a further study, if there wasn't some truth in that statement.
But hey, who knows !

[professor bang bang] 22/2/2018 14:50

Recruitment status: "Recruiting"

[stanman] 22/2/2018 14:49

Which meeting is that?

[waterloo01] 22/2/2018 14:47

Bermuda, they just added the clinical trial number.

[professor bang bang] 22/2/2018 14:40

They know Lupuzor is working and can feel it. In addition we know Lupuzor already beats GSK's Benlysta at 3 and 6 months, on the basis of the Phase 2b data, and has a completely benign side effects profile unlike Benlysta which has adverse side effects.

[bermudashorts] 22/2/2018 14:38

The Clinical Trials Register has been updated to show that the extension trial is now recruiting. I believe some extra trial centres may have been added too but would need to double check that when change history is updated.